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Paraneoplastic pemphigus (PNP) is an acquired auto-
immune disorder characterized by severe mucosal ero-
sion, and polymorphous cutaneous lesions associated 
with neoplasia. PNP patients have circulating autoan-
tibodies that bind to stratified and nonstratified epi-
thelia. Previously, we showed that envoplakin was a 
component of the antigen complex recognized by PNP 
sera. In the present study we generated a monoclonal 
antibody, EVP-YS, against human envoplakin. The 
antibody bound to keratinocyte cell surfaces and re-
acted with the 210-kDa PNP antigen, confirming its 
specificity for envoplakin. The variable regions of the 
heavy (H) and light (L) chain genes were cloned from 
the hybridoma and shown to belong to mouse H chain 
subgroup III and κ light chain subgroup V, respec-
tively. The L chain of EVP-YS was 98% identical to 
the κ chains of some autoantibodies and anti-nucleic 
acid antibodies, and had an identical amino acid se-
quence in all three complementary determining re-
gions, suggesting that the H chains determine the 
specificity of the EVP-YS-envoplakin interaction. The 
EVP-YS antibody can be used to evaluate the sensitiv-
ity and specificity of clinical, histological, and immu-
nological criteria for diagnosing PNP. 
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Introduction 
 
Paraneoplastic pemphigus (PNP) is an acquired autoim-
mune blistering disorder characterized by severe mucosal 
erosion, and polymorphous skin lesions in association 
with underlying neoplasia (Anhalt et al., 1990; Horn and 
Anhalt, 1992; Oursler et al., 1992). Circulating autoanti-
bodies in PNP patients bind not only to the cell surface of 
stratified squamous epithelia but also to simple, columnar 
and transitional epithelia, and immunoprecipitate antigen 
complexes consisting of five polypeptides with molecular 
masses of 250, 230, 210, 190, and 170 kDa (Anhalt et al., 
1990). These autoantibodies are pathogenic, as demon-
strated by passive transfer experiments (Anhalt et al., 
1990). We have previously shown that the 210 kDa PNP 
antigen is envoplakin, a member of the plakin family 
(Kim et al., 1997). It is now clear that PNP autoantibodies 
recognize a number of plakin family proteins including 
plectin, desmoplakin, BP230, envoplakin and periplakin 
(Aho et al., 1999; Mshoney et al., 1998). 
Plakin family proteins are expressed in tissues that ex-
perience mechanical stress, such as epithelia and muscle, 
where they play a vital role in maintaining tissue integrity 
by cross-linking cytoskeletal filaments and anchoring 
them to membrane complexes. Hence, both autoimmune 
and inherited diseases that affect plakins can lead to dis-
orders characterized by tissue fragility and skin blistering 
(Leung et al., 2002). Envoplakin is a component of the 
epidermal cornified envelope that is localized in the des-
mosomes of stratified epithelial cells. Its expression in-
creases along with the differentiation of keratinizing 
stratified squamous epithelia (Simon and Green, 1984). In 
the present study, we developed a monoclonal antibody 
against human recombinant envoplakin and, using the 
hybridoma cells, we sequenced the envoplakin-specific 
variable regions of the heavy and light chain cDNAs. This 
monoclonal antibody can be used to characterize the en-
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voplakin associated with PNP. 
 
 
Materials and Methods 
 
Preparation of glutathione (GST)-fused human envoplakin 
To produce antigen for generating monoclonal antibody against 
human envoplakin, a 1.4 kb EcoRI fragment of λ gt11 PNP 
DNA which contains coding sequences for part of the rod do-
main, the linker and the COOH-terminal C-domain of 210-kDa 
envoplakin (Kim et al., 1997) was inserted downstream of a 
cDNA encoding GST in pGEX4T-1 (Pharmacia). The resulting 
plasmid was transformed into E. coli DH5α, and the expressed 
GST-envoplakin was purified with GST Sepharose beads (Phar-
macia). The recombinant envoplakin was digested with thrombin 
and extracted from SDS/PAGE by electro-elution followed by 
dialysis in Tris-buffered saline (pH 7.2) at 4°C overnight (Fig. 1). 
 
Production of a monoclonal antibody to human envoplakin 
Ten mg of thrombin-treated envoplakin was mixed 1:1 with 
complete Freund’s adjuvant (Sigma) in phosphate-buffered sa-
line (PBS), and five mice were immunized intraperitoneally 
with this antigen. The immunized splenocytes were harvested 
and incubated with Sp2/0-Ag-14 myeloma cells in 50% PEG 
4000 for 2 weeks. The supernatants of the hybridoma cell cul-
tures were tested for anti-envoplakin antibody by enzyme-linked 
immunosorbant assay (ELISA). Cells giving positive signals 
were cloned through three rounds of selection by limiting dilu-
tion. 
 
Competition ELISA The affinity of hybridoma-derived EVP-
YS was evaluated by competition ELISA (Kim et al., 2001; 
Orfanoudakis et al., 1993). The amount of EVP-YS antibody 
giving half-maximal binding to envoplakin-coated plates was 
determined by ELISA by serial dilution of the hybridoma super-
natant. For this purpose, recombinant envoplakin (10 µg) was 
dispensed in 96-well plates and incubated at 4°C for overnight. 
The plates were washed, and the wells blocked with 1% BSA in 
PBS containing 0.05% Tween (PBS-T) for 2 h at room tempera-
ture. After washing, 100 µl aliquots of serial dilutions of the 
hybridoma culture supernatant were incubated for 2 h at room 
temperature. Following washing with PBS-T, rabbit anti-mouse 
IgG-peroxidase conjugate (DAKO) was added for 1 h. After 
washing, 100 µl of ABTS (KPL, MD, USA) was added to each 
well, and the O.D. was measured at 405 nm. For competition 
ELISA, serially diluted envoplakin was mixed with an equal 
volume of twice the concentration of EVP-YS antibody giving 
half-maximal binding, and incubated for 2 h at room tempera-
ture. The envoplakin-bound EVP-YS antibody solution was 
added the envoplakin- or periplakin-coated plates, and the rest 
of the assay was as described above. The envoplakin concentra- 
tion giving 50% inhibition of maximum binding represents the 
inhibition constant, Ki. 
 
Immunofluorescence microscopy Immunofluorescence mi- 
 
 
 
 
 
 
 
 
 
Fig. 1. Purification of recombinant envoplakin by Glutathione-
Sepharose column chromatography. Lane 1, total E. coli lysate; 
lane 2, flow-through following binding of the lysate to Glu-
tathione-Sepharose; lane 3, GST-Envoplakin following elution 
with reduced glutathione; lane 4, thrombin-digested GST-
Envoplakin; lane 5, the electro-eluted envoplakin used to immu-
nize mice. 
 
croscopy was performed essentially as described (Bahn et al., 
2002). Frozen sections (5 µm) of neonatal foreskin were air-
dried and incubated in PBS for 5 min, and then for 2 h at room 
temperature in PBS containing 10-fold diluted monoclonal anti-
envoplakin EVP-YS antibody. The sections were washed three 
times in PBS and incubated with FITC-conjugated rabbit anti-
mouse immunoglobulin (DAKO) for 1 h at room temperature, 
with three subsequent washes in PBS. Sections were mounted in 
glycerol/PBS solution and examined with a fluorescence micro-
scope. 
 
Immunoblot analysis Immunoblotting was performed as de-
scribed (Hashimoto et al., 1990). In brief, cultured human 
keratinocytes were lysed in SDS sample buffer [1.5% sodium 
dodecyl sulfate, 10 mM Tris-HCI, pH 6.8, 2 mM ethylenedia-
mine tetraacetic acid, 2 mM phenylmethylsulfonyl fluoride, 5% 
mercaptoethanol, 5 mg leupeptin, antipain, chymostain, and 
pepstain (Sigma) per ml], and homogenized with a glass ho-
mogenizer. Samples were boiled for 5 min and centrifuged at 
15,000 × g for 30 min. Proteins were separated by SDS-PAGE 
and transferred to nitrocellulose membranes that were cut into 
strips and incubated with patients’ IgG or monoclonal anti-
envoplakin antibody and then with peroxidase-conjugated rabbit 
anti-human or anti-mouse IgG (DAKO). Reactions were visual-
ized with 4-chloro-1-naphthol (Sigma) in the presence of 
0.025% H2O2. 
 
Cloning and sequencing of the envoplakin-specific variable 
regions of heavy (VH) and light (VL) chain cDNAs Total RNA 
was extracted from 1 × 107 hybridoma cells using Tri-reagent 
(Molecular, Cincinnati) and first-strand cDNA was made in 20 
µl reaction mixtures in reverse transcriptase buffer [50 mM Tris-
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT], with 5 
µg total RNA and Moloney murine leukemia virus reverse tran-
scriptase, 250 ng random primers and Rnasin (Promega). The 
cDNA of the VH gene was PCR-amplified with a reverse Cγ 
primer complementary to the sequence of the constant region of 
the γ (Cγ) chain gene, and forward H1-3 primers complementary
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Table 1. Primers used for cloning EVP-YS VL and VH genes. 
Name Sequence (5′ → 3′) Groups 
Cκ CCAGGGGCCAGTGGATAGACAAGCTTGGGTGTCGTTT IgG L-chain constant 
Cγ AAGATGGATCCAGTTGGTGCAGCATCAGC IgG H-chain constant 
H1 (C/G)CAGCTGCAG(C/G)AGTC(A/T)GG IgG H-chain (IB, IIA)* 
H2 (C/G)(A/C)AACTGCAG(C/G)AGTC(A/T)GG IgG H-chain (IIA, B, C, VA)* 
H3 (C/G)(A/C)AGCTGCAG(C/G)AGTC(A/T)GG IgG H-chain (IIIA, C, D)* 
L1 GACATTGTGATG(A/T)C(A/T)CAGTCTCCA IgG L-chain (I)* 
L2 GA(G/C)AGGTGCAGCT(T/G)(C/A)AGGAGTCAGGA IgG L-chain (III)* 
L3 (A/G)A(A/C)ATTGTGCTGAC(A/C)CA(A/G)TCTCC(A/T) IgG L-chain (V)* 
* Indicates mouse H- and L-chain groups as described by Kabat et al. (1991). 
 
 
to the DNA sequences of the N-termini of heavy γ chain genes 
(Table 1). The cDNA of the VL gene was amplified with a Cκ 
reverse primer and L1-3 forward primers complementary to the 
DNA sequences of the N-termini of light κ chains under the 
same conditions as used for the VH genes. The PCR products 
were cloned into pBluescript KS(+) (Stratagene) and sequenced 
by the dideoxy chain termination method. 
 
 
Results and Discussion 
 
To produce monoclonal antibodies specific for human 
envoplakin, we expressed a GST-fusion of envoplakin in 
bacteria, and electro-eluted it from SDS-PAGE. The rena-
tured recombinant protein was used as antigen to immu-
nize BALB/c mice (Fig. 1), and the splenocytes obtained 
from an envoplakin-immune mouse were fused with mye-
loma SP2/0 cells. Of the monoclonal antibodies produced, 
EVP-YS bound to purified envoplakin with high affinity 
(data not shown). Figure 2A shows that a 1:20 dilution of 
the culture supernatant of the EVP-YS hybridoma recog-
nized recombinant envoplakin but not periplakin. Compe-
tition ELISA showed that the envoplakin concentration 
giving 50% inhibition of maximum binding was 2.2 × 
10−8 M (Fig. 2B). Periplakin did not compete with en-
voplakin for binding. Because the EVP-YS hybridoma 
was generated using a non-natural form of the antigen, we 
assessed whether the antibody recognized endogenous 
envoplakin expressed on human keratinocytes. Indirect 
immunofluorescence assays showed that the antibody 
bound to the cell surface of the keratinocytes of human 
skin. Staining with the antibody was more prominent in 
the upper spinous and granular layers, just as it is with 
affinity-purified IgG from PNP patients (Kim et al., 1997) 
(Fig. 3A). Immunoblot analysis of proteins extracted from 
cultured keratinocytes revealed that EVP-YS bound to the 
210-kDa PNP antigen (Fig. 3B, lane indicated by EVP-
YS). We also showed that monoclonal antibody against 
periplakin (PRP-YS) recognized a major 190-kDa mo-
lecular weight species. Both envoplakin and periplakin 
are PNP antigens that react strongly with PNP sera (Bor- 
A           B 
 
 
 
 
 
 
 
 
Fig. 2. The specificity of EVP-YS monoclonal antibody. A. 
Immunoblot analysis using a 1:20 dilution of the culture super-
natant of EVP-YS hybridoma cells with GST-fused envoplakin 
and periplakin. B. Competition ELISA for determining the affin-
ity of EVP-YS. See Materials and Methods for details. Com-
petition data for envoplakin and periplakin against envoplakin-
bound EVP-YS antibody are presented. 
 
 
radori et al., 1998). Indeed, PNP patients’ serum detected 
a characteristic doublet of 210-kDa and 190-kDa (Fig. 3B, 
lane indicated by PNP serum), corresponding to the en-
voplakin and periplakin bands detected by their respective 
monoclonal antibodies. These results indicate that EVP-
YS is capable of binding to keratinocyte cell surfaces 
where it presumably binds to envoplakin. 
The VH cDNA of monoclonal antibody EVP-YS was 
prepared from total RNA of EVP-YS hybridoma cells and 
cloned by RT-PCR with a reverse primer that hybridizes 
to the constant region (Cγ primer) and a forward primer 
H3 (Table 1). The PCR product, a DNA fragment of ap-
proximately 380 bp, was cloned into pBluescript. The 
nucleotide sequences and deduced amino acid sequences 
of the VH region are shown in Fig. 4A. Comparison of the 
amino acid sequence of the EVP-YS VH region with the 
sequence of 10 murine VH groups indicates that the VH 
segment of EVP-YS belongs to the subgroup III, accord- 
ing to Kabat’s classification (Kabat et al., 1991). PCR 
using a forward L3 primer and reverse Cκ primer was 
performed to clone the VL cDNA of EVP-YS. The de-
duced amino acid sequence revealed a typical mouse vari-
able region κ light chain (Fig. 4B), with 98% homology to 
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Fig. 3. EVP-YS monoclonal antibody stains the keratinocyte 
cell surface and reacts with the 210-kDa PNP antigen. A. Upper, 
indirect immunofluorescence analysis of normal skin shows 
staining of the keratinocyte surface. Staining is more prominent 
in the upper spinous and granular layer. Lower, background 
staining with secondary antibody conjugated with FITC. B. 
Immunoblot analysis of cultured keratinocyte extract. EVP-YS, 
monoclonal antibody against human envoplakin; PRP-YS, 
monoclonal antibody against periplakin; and PNP serum, PNP 
patients’ serum. 
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Fig. 4. Nucleotide sequence of the EVP-YS variable region gene 
and the deduced amino acid sequence. Complementary deter-
mining regions (CDRs) are underlined. (A) VH gene and (B) VL 
gene. 
the light chains of autoantibodies and anti-nucleic acid 
antibodies, and with identical amino acid sequences in 
complementary determining region (CDR)-1, -2 and -3 
(Brown et al., 1998). Other light chains of antibodies such 
as anti-keratin, anti-p53 and anti-estrogen receptor, have 
also shown homology to sequences in GenBank. Please 
explain--editor. Since the EVP-YS light chain does not 
have a unique specificity for envoplakin, its specificity is 
probably determined by its heavy chains. 
PNP is an autoimmune blistering disease characterized 
by the production of autoantibodies mainly directed against 
proteins of the plakin family, which include envoplakin and 
periplakin. Although autoantibody specificities overlap be-
tween the different types of pemphigus such as PNP, pem-
phigus vulgaris (PV) and pemphigus foliaceus (PF), the 
detection of envoplakin by immunoblotting is both a sensi-
tive and specific feature of PNP (Joly et al., 2000). Thus, 
we believe that monoclonal antibody EVP-YS will be use-
ful for evaluating the sensitivity and specificity of clinical, 
histological, and immunological criteria for the diagnosis 
of PNP. 
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